-- China Medical System's (HKG:0867, SGX:8A8) new drug application for the seasonal allergic rhinitis indication of MG-K10 was accepted by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.
The firm holds co-development rights, excluding the indication of atopic dermatitis, and exclusive commercialization rights for the drug.
The drug is proposed to treat adult patients with moderate-to-severe seasonal allergic rhinitis whose symptoms are inadequately controlled following treatment with intranasal corticosteroid.